Introduction
============

Polypoidal choroidal vasculopathy (PCV) was initially described as a distinct choroidal vascular abnormality characterized by recurrent subretinal pigment epithelial bleeding and serosanguineous complications in the posterior pole.[@b1-opth-8-1689]--[@b4-opth-8-1689] Later on, the spectrum of the disease was expanded.[@b5-opth-8-1689]--[@b7-opth-8-1689] However, it remains controversial whether PCV is a true distinct entity or a variant of type 1 choroidal neovascularization (CNV), despite reportedly different clinical characteristics, natural course and response to treatment.[@b4-opth-8-1689] Both entities usually show characteristics of an occult lesion on fluorescein angiography and indocyanine green angiography (ICGA) may show hyperfluorescent "hot spots" in both, although a cluster of subretinal hot spots is characteristic of PCV, especially when associated with a branching choroidal vascular network (BVN).[@b8-opth-8-1689] Early time-domain optical coherence tomography (TD-OCT) studies showed that the polypoidal lesions as well as the BVN as seen on ICGA were associated with "atypical" pigment epithelial detachments (PEDs), and careful review of the illustrations suggests that these lesions may be located anterior to Bruch membrane.[@b9-opth-8-1689],[@b10-opth-8-1689] However, TD-OCT has a poor definition of the outer retinal layers, and while the findings are suggestive of a sub-retinal pigment epithelial (sub-RPE) location of PCV, they are not confirmatory. Spectral-domain optical coherence tomography (SD-OCT) has a superior ability to resolve the outer retinal layers and may offer an opportunity to better define the location of PCV lesions in vivo. In this study, we examined patients with a typical presentation of PCV both clinically and angiographically, using SD-OCT in an effort to characterize the RPE and sub-RPE space in this disease and localize the PCV lesions seen on ICGA.

Patients, materials and methods
===============================

A case series of 17 eyes of 15 consecutive patients diagnosed with PCV was conducted following approval by the Institutional Review Board at the King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia. The diagnosis of PCV was based on typical clinical and angiographic findings, including ICGA. All ICGA studies were performed using a scanning laser ophthalmoscope (Heidelberg Retina Angiograph 2 \[HRA2\]; Heidelberg Engineering GmbH, Heidelberg, Germany). Clinical criteria for the diagnosis of PCV included serous, serosanguineous, and hemorrhagic detachments of the retina, and RPE in the posterior pole or periphery in a relatively elderly patient; exudation, reddish-orange "inner choroidal" vascular abnormalities and nodules; general rarity of drusen; poor response to prior anti-vascular endothelial growth factor agents; an occult CNV picture on fluorescein angiography; and evidence of deep hyperfluorescent aneurismal dilatations on ICGA with or without a BVN.[@b11-opth-8-1689],[@b12-opth-8-1689] Two eyes were seen by remote consultation. Both were originally diagnosed with age-related macular degeneration (AMD), and one was treated with intravitreal anti-vascular endothelial growth factor injections. Only angiographic and SD-OCT data are available, but not detailed historical and follow-up data. Although we do not have detailed historical and follow-up data for these two eyes, we decided to include them in this series because we had enough angiographic and SD-OCT information to make the diagnosis and analyze the imaging findings for the purpose of this study.

Following a complete ophthalmic evaluation, all eyes were imaged with macular SD-OCT including line scans passing through the aneurismal dilatations noted on ICGA. Enhanced depth imaging was not performed. SD-OCT imaging was performed using a Spectralis unit (Heidelberg Engineering GmbH) in all cases. All eyes underwent a macular cube acquisition protocol with a scan pattern of 25°C×20°C consisting of a raster of 19 horizontal line-scans with a scanning density of 512 A-scans per line and an averaging parameter of 9 times (retinal thickness analysis \[RTA\] =9) while correcting for eye movements using the proprietary TruTrack function. In addition, single line scans passing through the aneurismal dilatations noted on ICGA were obtained with a scanning density of 768 A-scans per line and an averaging parameter of 25 times (RTA =25). All OCT scans were analyzed by one of us looking at the intraretinal, subretinal, and sub-RPE changes.

Results
=======

The age of the patients ranged from 40 to 80 years (mean age, 68.23±11.02 years), and the visual acuity of the involved eye ranged from 20/50 to 1/200 (reading the 20/200 optotype at 1 foot) ([Table 1](#t1-opth-8-1689){ref-type="table"}). Two patients had both eyes affected with PCV at presentation. Thirteen eyes were previously diagnosed with wet AMD; three eyes had other associated diagnoses including central serous choroidopathy, presumed intraocular tuberculosis, and reticular pattern dystrophy of the RPE; and the remaining eye was incorrectly thought to have choroidal melanoma. Fluorescein angiography disclosed features of occult without classic CNV in the form of stippled hyperfluorescence with minimal late leakage, or minimally classic CNV in 14 eyes, and predominantly classic CNV in three eyes. All eyes had typical polyps on angiography, and five had a clearly associated BVN on ICGA.

On SD-OCT cube imaging, all 17 eyes showed subretinal fluid (SRF) in association with PEDs. The extent of SRF and severity of PED was variable. Five of the 17 eyes had only SRF without intraretinal fluid, and the remaining 12 had both SRF and intraretinal fluid. SD-OCT line scans passing through the PCV lesions seen on ICGA showed remarkably unifying features in all eyes, in that all had a sub-RPE hyper-reflective tissue similar to what is seen in type 1 (occult) CNV. None of the eyes showed evidence of CNV in the subretinal space (type 2 CNV). All eyes had PEDs that were atypical in morphology and content. These PEDs assumed a corrugated or "bumpy" configuration ([Figure 1](#f1-opth-8-1689){ref-type="fig"}). In some of the cases, the bumps of the RPE line were markedly abrupt, yielding an "M-shaped" or even a "QRS complex-shaped" PED ([Figure 2](#f2-opth-8-1689){ref-type="fig"}) on some of the OCT line scans. In addition, careful assessment of the contents of these atypical PEDs disclosed well-delineated, round-oval, sub-RPE cavities with low to medium reflectivity centrally, and hyper-reflective borders resembling vascular cavities. These structures were always adherent to the posterior surface of the elevated RPE line, which appeared to be draped over them, and corresponded to the polyps seen on ICGA ([Figures 1](#f1-opth-8-1689){ref-type="fig"}--[5](#f5-opth-8-1689){ref-type="fig"}). In the eyes with a clearly defined, associated BVN seen on ICGA, the SD-OCT line scans of the corresponding area disclosed a moderately hyper-reflective tissue underneath the elevated RPE ([Figure 4](#f4-opth-8-1689){ref-type="fig"}). We speculate that this moderately hyper-reflective tissue and the round-oval, sub-RPE cavities represent the BVN and the polyps, respectively. In addition, both the polyps and the BVN were located anterior to Bruch membrane.

Discussion
==========

These SD-OCT findings demonstrate that the vascular lesions seen on ICGA in PCV are not located in the inner choroid, as initially suggested,[@b1-opth-8-1689],[@b3-opth-8-1689],[@b13-opth-8-1689] but rather in the sub-RPE space within an atypical PED and anterior to Bruch membrane. These findings are almost identical to those of Khan et al[@b14-opth-8-1689] who reported 18 such cases with SD-OCT localization of the PCV lesions to the sub-RPE space. In addition, several other studies have suggested similar localization of the PCV lesions.[@b4-opth-8-1689],[@b9-opth-8-1689],[@b10-opth-8-1689],[@b15-opth-8-1689]--[@b18-opth-8-1689] This anatomical location is similar to that of type 1 CNV.[@b16-opth-8-1689],[@b17-opth-8-1689],[@b19-opth-8-1689]--[@b22-opth-8-1689] This, in turn, supports the notion that PCV is a variant of type 1 CNV and is further evidence that PCV is a neovascular growth pattern, rather than a distinct clinical entity of the native inner choroidal vessels. Our study demonstrates that the two main SD-OCT distinguishing features of PCV lesions are: 1) the polyps seen in the sub-RPE space adherent to the posterior surface of the RPE; and 2) the atypical bumpy PEDs that can be M-shaped or even QRS complex-shaped, as illustrated in this study. In our experience, the combination of these two features is pathognomonic of PCV. These SD-OCT findings may be of value in at least strongly suspecting the diagnosis in the absence of ICGA, which is not as widely utilized as fluorescein angiography. This, in turn, may prove helpful in treatment modification, particularly in cases resistant to conventional therapy with anti-vascular endothelial growth factor agents.

The suggestion that PCV is a neovascular process and a variant of type 1 CNV, rather than a distinct clinical entity, is also supported by clinical and histological findings. Clinical data suggest that PCV may complicate several maculopathies predisposing to CNV, particularly AMD. Most of the cases described in Caucasians to date, and many non-Caucasian cases, have been previously known to have AMD.[@b14-opth-8-1689],[@b23-opth-8-1689],[@b24-opth-8-1689] Also, drusen are noted in many cases of PCV, and most cases have an occult presentation on fluorescein angiography.[@b4-opth-8-1689],[@b8-opth-8-1689] In addition, most patients with the disease are older than 50 years, and many have associated hypertension, similar to AMD.[@b25-opth-8-1689] Finally, both inflammatory markers and genetic risk alleles associated with AMD have also been reported to be associated with PCV.[@b26-opth-8-1689]--[@b28-opth-8-1689]

Histological data from both submacular membranectomy specimens[@b28-opth-8-1689]--[@b32-opth-8-1689] and enucleation specimens[@b33-opth-8-1689]--[@b35-opth-8-1689] strongly support the sub-RPE location of the PCV lesions, and their similarities to type 1 CNV. Several submacular membranectomy studies reported the presence of large dilated blood vessels subjacent to the RPE and in close proximity to a layer of diffuse drusen and degenerated RPE, in an almost identical fashion to our SD-OCT findings.[@b29-opth-8-1689]--[@b32-opth-8-1689] The main histological difference between the two entities is in relation to the size of the neovessels in the sub-RPE space in that PCV is characterized by atypically large blood vessels with unusual dilatations, unlike type 1 CNV, which is characterized by a fine network of predominantly capillary-sized vessels in the early stages, which may evolve into arteries and veins with time.[@b19-opth-8-1689],[@b20-opth-8-1689],[@b29-opth-8-1689]--[@b37-opth-8-1689] Data from enucleation studies[@b33-opth-8-1689]--[@b35-opth-8-1689] of eyes with presumed PCV have been less conclusive, largely because of the advanced nature of the disease process at the time of enucleation whereby all of them were either associated with end-stage hemorrhagic, or disciform processes. In two specimens, no polypoidal lesions could be demonstrated, but only sub-RPE and/or subretinal fibrovascular proliferation traversing breaks in Bruch membrane similar to those seen in typical macular degeneration could be seen.[@b34-opth-8-1689],[@b35-opth-8-1689] In a third specimen, large dilated and thin-walled vessels were noted in the sub-RPE space/intra-Bruch region and were thought to originate from the ciliary vessels.[@b33-opth-8-1689] Even though the latter (third) enucleation specimen is more convincing than the former two, the associated massive hemorrhagic and disciform complications, as well as the focal bone formation, suggest chronicity and advanced disease, making the findings less definitive. However, the authors conclude that PCV may be a form of AMD due to the sub-RPE/intra-Bruch location of the neovessels.

Some of the reasons that led to the suggestion that PCV is a distinct entity from AMD included the clinical presentation predominantly in the peripapillary area with a unique ICGA appearance, its ethnic predilection, the relatively favorable natural history, and its different response to therapy.[@b4-opth-8-1689],[@b5-opth-8-1689],[@b7-opth-8-1689] However, all these are not sufficient reasons to make PCV a distinct entity. CNV in AMD may also be peripapillary in location. In addition, subsequent studies on PCV have demonstrated that the disease affects the macular area much more frequently than originally thought.[@b4-opth-8-1689],[@b5-opth-8-1689],[@b38-opth-8-1689] The relatively favorable natural history of PCV[@b39-opth-8-1689] and its different response to therapy[@b40-opth-8-1689]--[@b42-opth-8-1689] also do not negate the hypothesis that PCV is a variant of type 1 CNV. For example, type 1 CNV is also known to have a more favorable natural history than type 2 (classic) CNV[@b43-opth-8-1689],[@b44-opth-8-1689] as well as a different response to some forms of therapy,[@b45-opth-8-1689]--[@b47-opth-8-1689] yet both can be variants of the same disease, such as neovascular AMD. In other words, having a different natural history and response to therapy does not necessarily make PCV a distinct entity. Moreover, the relatively better natural history of PCV may be at least in part directly related to its sub-RPE location and to it being a variant of type 1 CNV. The ethnic predilection of PCV remains unexplained.

In conclusion, these SD-OCT findings localize the vascular lesions in PCV to the sub-RPE space and strongly suggest that PCV is a variant of type 1 CNV. They also constitute strong complementary evidence to the available clinical and histological data supporting the hypothesis that PCV is not a distinct clinical entity but rather a neovascular process, which can complicate several entities, predominantly AMD, but also central serous choroidopathy, angioid streaks, myopia, and others. Therefore, we suggest the descriptive term "polypoidal PED" to describe the characteristic clinical presentation previously termed PCV and to categorize it as a third type of PED associated with type 1 CNV, in addition to serous and fibrovascular PED.
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![The right eye of a 66-year-old male (case 8) with polypoidal choroidal vasculopathy, initially diagnosed with age-related macular degeneration.\
**Notes:** (**A**) Color fundus photograph showing subretinal fluid with hard exudates and orange--red nodules in the macula affecting the center of the fovea. (**B**) Late phase fluorescein angiography frame showing extrafoveal stippled hyperfluorescence with minimal leakage suggestive of an occult choroidal neovascular membrane. (**C**) Indocyanine green angiography revealing a well-defined branching vascular network with polypoidal terminations outside the foveal area. (**D**) Spectral-domain optical coherence tomography cross-sectional scan corresponding to the interrupted white line in (**C**). Note the atypical "bumpy" and "M-shaped" pigment epithelial detachment with well-delineated, round-oval, sub-RPE cavities (blue arrows) corresponding to the polyps in (**C**). The polyps are adherent to the posterior surface of the elevated RPE line and are anterior to Bruch membrane (white arrow).\
**Abbreviation:** RPE, retinal pigment epithelial.](opth-8-1689Fig1){#f1-opth-8-1689}

![The right eye of a 75-year-old male (case 7) with polypoidal choroidal vasculopathy initially diagnosed with central serous choroidopathy.\
**Notes:** (**A**) Color fundus photograph showing subretinal fluid with hard exudates, hemorrhage, orange--red nodules just inferior to the exudates, and a pigment epithelial detachment (PED) in the macula. (**B**) Fluorescein angiogram confirming the serosanguineous PED that is notched. Note the "ink-blot" leakage at the temporal edge of the PED and the irregular fluorescence superiorly. (**C**) and (**D**) Indocyanine green angiography revealing a fine branching vascular network with small polypoidal dilatations along the superior border of the PED. (**E**) and (**F**) Vertical and horizontal spectral-domain optical coherence tomography cross-sectional scans corresponding to the interrupted white lines in (**C**). Note the atypical "QRS complex-shaped" (**E**) and "M-shaped" (**F**) PEDs with well-delineated, round-oval, sub-RPE cavities (blue arrows) corresponding to the polyps in (**C**). The polyps are adherent to the posterior surface of the elevated RPE line and are anterior to Bruch membrane (white arrow).\
**Abbreviation:** RPE, retinal pigment epithelial.](opth-8-1689Fig2){#f2-opth-8-1689}

![The right eye of a 73-year-old male (case 6) with polypoidal choroidal vasculopathy, who was diagnosed with choroidal melanoma.\
**Notes:** (**A**) Color fundus photograph showing subretinal hemorrhage with extensive hard exudates, and orange--red nodules superonasal to the optic nerve head. (**B**) Fluorescein angiogram showing stippled hyperfluorescence, blockage from blood, and minimal leakage, suggestive of an occult choroidal neovascular membrane. (**C**) and (**D**) Indocyanine green angiography revealing a fine branching vascular network with small polypoidal dilatations. (**E**) and (**F**) Horizontal and vertical spectral-domain optical coherence tomography cross-sectional scans corresponding to the interrupted white lines in (**D**). Note the atypical "M-shaped" PED with well-delineated, round-oval, sub-RPE cavities (blue arrows) corresponding to the polyps in (**D**). The polyps are adherent to the posterior surface of the elevated RPE line.\
**Abbreviations:** PED, pigment epithelial detachment; RPE, retinal pigment epithelial.](opth-8-1689Fig3){#f3-opth-8-1689}

![The right eye of a 71-year-old male (case 11) with bilateral idiopathic choroidal folds and polypoidal choroidal vasculopathy initially diagnosed with age-related macular degeneration.\
**Notes:** (**A**) Color fundus photograph showing subretinal fluid and hemorrhage in the fovea and peripapillary hard exudates. (**B**) Indocyanine green angiography revealing a branching vascular network (BVN) with small multiple polypoidal dilatations. (**C**--**E**) Horizontal spectral-domain optical coherence tomography cross-sectional scans corresponding to the labeled white lines in (**B**). Note the atypical corrugated, bumpy, and "M-shaped" PEDs with well-delineated, round-oval, sub-RPE cavities (blue arrows) corresponding to the polyps in (**B**). The polyps are adherent to the posterior surface of the elevated RPE line. Also note that the area of the BVN in (**B**) (white arrow), corresponds to a moderately hyper-reflective tissue in (**C**) sandwiched between the elevated RPE line and Bruch membrane (white arrow in \[**C**\]). Both the polyps and the BVN are located anterior to Bruch membrane (**C**--**E**).\
**Abbreviations:** PED, pigment epithelial detachment; RPE, retinal pigment epithelial.](opth-8-1689Fig4){#f4-opth-8-1689}

![Four other eyes with spectral-domain optical coherence tomography showing atypical pigment epithelial detachments (PEDs) with polyps (blue arrows) adherent to the posterior surface of the elevated RPE line and anterior to Bruch membrane (white arrows).\
**Notes:** (**A1**) and (**A2**) are vertical and horizontal line scans passing through a polypoidal lesion of the same eye, respectively. (**B**--**D**) are line scans passing through polypoidal lesions of three other eyes. Note the varying patterns of an "M-shaped" PED in (**A1**), (**B**), and (**C**).\
**Abbreviation:** RPE, retinal pigment epithelial.](opth-8-1689Fig5){#f5-opth-8-1689}

###### 

Patient characteristics and disease course[\*](#tfn1-opth-8-1689){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case no   Age      Sex      Involved eye   VA at presentation[\*\*](#tfn2-opth-8-1689){ref-type="table-fn"}   VA at last follow-up[\*\*](#tfn2-opth-8-1689){ref-type="table-fn"}   Associated diagnoses                     Treatment prior to referral × number of treatments   Treatment after diagnosis × number of treatments
  --------- -------- -------- -------------- ------------------------------------------------------------------ -------------------------------------------------------------------- ---------------------------------------- ---------------------------------------------------- --------------------------------------------------
  1         76       M        OD             20/125                                                             2/200                                                                AMD                                      Avastin ×7                                           PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×1

  2         74       F        OD             20/200                                                             20/400                                                               Presumed intraocular TB                  Systemic anti-TB                                     Focal laser ×3

  OS        20/125   20/300   AMD            None                                                               Focal laser ×1\                                                                                                                                                    
                                                                                                                Avastin ×3                                                                                                                                                         

  3         55       M        OD             3/200                                                              20/400                                                               AMD                                      Avastin ×2                                           PDT ×3\
                                                                                                                                                                                                                                                                                   Avastin ×9\
                                                                                                                                                                                                                                                                                   Lucentis ×1

  4         75       M        OS             1/200                                                              20/400                                                               AMD                                      Avastin ×3                                           PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×1

  5         40       M        OS             20/50                                                              20/30                                                                AMD                                      Avastin ×3                                           Avastin ×4

  6         73       M        OD             20/50                                                              20/40                                                                Choroidal melanoma                       None                                                 PPV for vitreous hemorrhage + focal laser

  7         61       M        OD             20/50                                                              20/30                                                                CSC                                      Avastin ×4                                           PDT ×3\
                                                                                                                                                                                                                                                                                   Avastin ×1\
                                                                                                                                                                                                                                                                                   Kenalog ×3\
                                                                                                                                                                                                                                                                                   Lucentis ×7

  8         66       M        OD             20/100                                                             20/80                                                                AMD                                      None                                                 PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×6\
                                                                                                                                                                                                                                                                                   Decadron ×1\
                                                                                                                                                                                                                                                                                   Lucentis ×1

  9         67       M        OD             20/100                                                             20/60                                                                AMD                                      None                                                 None

  10        79       F        OD             20/400                                                             20/200                                                               AMD                                      None                                                 PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×2

  OS        20/50    20/40                   None                                                               PDT ×1\                                                                                                                                                            
                                                                                                                Avastin ×1                                                                                                                                                         

  11        71       M        OD             20/80                                                              20/70                                                                AMD                                      None                                                 PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×1

  12        80       M        OD             20/70                                                              20/70                                                                AMD                                      None                                                 Focal laser

  13        70       F        OD             20/50                                                              20/125                                                               Reticular pattern dystrophy of the RPE   Avastin ×1                                           PDT ×1\
                                                                                                                                                                                                                                                                                   Avastin ×11\
                                                                                                                                                                                                                                                                                   Lucentis ×1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Two eyes were seen by remote consultation. Both were originally diagnosed with AMD and one was treated with intravitreal anti-vascular endothelial growth factor injections. Only angiographic and spectral-domain OCT data are available but not detailed historical and follow-up data. So, they were not included in the table even though they were included in the series analysis.

VA readings presented as 1/200, 2/200, and 3/200 mean readings of the 200E optotype taken at 1, 2, and 3 feet, respectively.

**Abbreviations:** no, number; VA, visual acuity; M, male; F, female; AMD, age-related macular degeneration; PDT, photodynamic therapy; OD, right eye; OS, left eye; TB, tuberculosis; CSC, central serous choroidopathy; RPE, retinal pigment epithelium; OCT, optical coherence tomography; PPV, pars plana vitrectomy.
